HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

Rhea-AI Summary

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference in New York City on September 28, 2022. CEO John Lubniewski will join the panel discussion titled “Predictive Biomarkers, Sequencing and Diagnostics, Oh My!” at 9:50 am ET. HTG focuses on advancing precision medicine through transcriptome-wide profiling technology, enhancing diagnostic tools, and supporting drug discovery across various diseases. For additional inquiries or meetings, attendees should contact their Cantor Fitzgerald sales representative.

TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) --  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

John Lubniewski, HTG CEO will be a participant in the panel discussion, “Predictive Biomarkers, Sequencing and Diagnostics, Oh My!” at 9:50 am ET on September 28, 2022.

For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative.

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

HTG Investor Contact:        
                        
Ashley Robinson                        
LifeSci Advisors                         
Phone: (617) 430-7577                
Email: arr@lifesciadvisors.com        

FAQ

What is HTG Molecular Diagnostics participating in on September 28, 2022?

HTG Molecular Diagnostics is participating in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference.

Who will represent HTG at the conference?

CEO John Lubniewski will represent HTG and participate in a panel discussion.

What is the topic of the panel discussion involving HTG?

The panel discussion is titled “Predictive Biomarkers, Sequencing and Diagnostics, Oh My!”

What time is HTG's panel discussion scheduled for?

The panel discussion is scheduled for 9:50 am ET on September 28, 2022.

What technology does HTG Molecular Diagnostics focus on?

HTG focuses on transcriptome-wide profiling technology to advance precision medicine.